Ataraxis AI to Transform Precision Medicine in Cancer Care with $20.4 Million Series A
Ataraxis AI has secured a $20.4 million Series A financing round led by AIX Ventures, with participation from notable investors including Peter Thiel and former Oscar Health (NYSE: OSCR) CEO Mario Schlosser. The company's AI foundation model, Kestrel, powers their first product Ataraxis Breast, which has shown to be 30% more accurate than current breast cancer care standards in clinical validation.
The platform is set to launch for clinical use across the United States later this year. The funding will support expanding treatment selection capabilities within and beyond breast cancer. The company has formed a Clinical Advisory Board featuring oncology leaders from top health systems, including experts from Northwell Lenox Hill, Yale Cancer Center, UPMC Hillman Cancer Center, and NYU.
Ataraxis AI ha ottenuto un finanziamento di 20,4 milioni di dollari nella Serie A, guidato da AIX Ventures, con la partecipazione di investitori di spicco tra cui Peter Thiel e l'ex CEO di Oscar Health (NYSE: OSCR) Mario Schlosser. Il modello di fondazione AI dell'azienda, Kestrel, alimenta il loro primo prodotto Ataraxis Breast, che ha dimostrato di essere 30% più accurato rispetto agli attuali standard di cura del cancro al seno nella validazione clinica.
La piattaforma è prevista per il lancio per uso clinico negli Stati Uniti entro la fine di quest'anno. Il finanziamento supporterà l'espansione delle capacità di selezione dei trattamenti sia per il cancro al seno che oltre. L'azienda ha formato un Comitato Consultivo Clinico composto da leader in oncologia provenienti dai migliori sistemi sanitari, inclusi esperti di Northwell Lenox Hill, Yale Cancer Center, UPMC Hillman Cancer Center e NYU.
Ataraxis AI ha conseguido una ronda de financiación de 20,4 millones de dólares en la Serie A, liderada por AIX Ventures, con la participación de inversores destacados como Peter Thiel y el ex CEO de Oscar Health (NYSE: OSCR) Mario Schlosser. El modelo de fundación de IA de la empresa, Kestrel, impulsa su primer producto Ataraxis Breast, que ha demostrado ser un 30% más preciso que los estándares actuales de atención del cáncer de mama en validación clínica.
La plataforma está prevista para lanzarse para uso clínico en los Estados Unidos a finales de este año. La financiación apoyará la expansión de las capacidades de selección de tratamientos dentro y más allá del cáncer de mama. La empresa ha formado un Consejo Asesor Clínico con líderes en oncología de los principales sistemas de salud, incluidos expertos de Northwell Lenox Hill, Yale Cancer Center, UPMC Hillman Cancer Center y NYU.
Ataraxis AI는 AIX Ventures가 주도하고 Peter Thiel 및 전 Oscar Health (NYSE: OSCR) CEO Mario Schlosser와 같은 저명한 투자자들이 참여한 2040만 달러 시리즈 A 자금을 확보했습니다. 이 회사의 AI 기반 모델인 Kestrel은 첫 번째 제품인 Ataraxis Breast의 동력을 제공하며, 이는 임상 검증에서 현재의 유방암 치료 기준보다 30% 더 정확한 것으로 나타났습니다.
이 플랫폼은 올해 말 미국 전역에서 임상 사용을 위해 출시될 예정입니다. 자금은 유방암 내외의 치료 선택 능력 확장을 지원할 것입니다. 이 회사는 Northwell Lenox Hill, Yale Cancer Center, UPMC Hillman Cancer Center 및 NYU의 전문가를 포함한 주요 의료 시스템의 종양학 리더들로 구성된 임상 자문 위원회를 구성했습니다.
Ataraxis AI a sécurisé un financement de 20,4 millions de dollars lors d'une série A, dirigé par AIX Ventures, avec la participation d'investisseurs notables, dont Peter Thiel et l'ancien PDG d'Oscar Health (NYSE: OSCR) Mario Schlosser. Le modèle de fondation AI de l'entreprise, Kestrel, alimente leur premier produit Ataraxis Breast, qui a montré qu'il était 30% plus précis que les normes actuelles de soins du cancer du sein lors de la validation clinique.
La plateforme devrait être lancée pour un usage clinique aux États-Unis plus tard cette année. Le financement soutiendra l'expansion des capacités de sélection des traitements dans le cancer du sein et au-delà. L'entreprise a formé un Conseil consultatif clinique composé de leaders en oncologie issus des meilleurs systèmes de santé, y compris des experts de Northwell Lenox Hill, du Yale Cancer Center, du UPMC Hillman Cancer Center et de NYU.
Ataraxis AI hat eine 20,4 Millionen Dollar Serie A Finanzierungsrunde gesichert, die von AIX Ventures geleitet wurde, mit Beteiligung von prominenten Investoren wie Peter Thiel und dem ehemaligen CEO von Oscar Health (NYSE: OSCR) Mario Schlosser. Das KI-Grundlagenmodell des Unternehmens, Kestrel, treibt ihr erstes Produkt Ataraxis Breast an, das in der klinischen Validierung 30% genauer ist als die aktuellen Standards der Brustkrebsversorgung.
Die Plattform soll noch in diesem Jahr für die klinische Nutzung in den Vereinigten Staaten eingeführt werden. Die Finanzierung wird die Erweiterung der Behandlungsauswahlmöglichkeiten innerhalb und außerhalb von Brustkrebs unterstützen. Das Unternehmen hat einen klinischen Beirat mit führenden Onkologen aus den besten Gesundheitssystemen gebildet, darunter Experten von Northwell Lenox Hill, Yale Cancer Center, UPMC Hillman Cancer Center und NYU.
- Secured $20.4M Series A funding
- Clinical validation shows 30% higher accuracy than current standards
- Imminent US market launch
- Strong advisory board with leading oncology experts
- Technology requires less data and computational power than competitors
- Product not yet commercially available
- to breast cancer initially
- Clinical validation results pending peer review
With new backing from AIX Ventures, Peter Thiel, and healthcare and AI pioneers, Ataraxis AI is positioned to rapidly bring its first offering, Ataraxis Breast, to market
Founded by Jan Witowski, MD, PhD, and Krzysztof Geras, PhD, Ataraxis AI is reshaping cancer diagnostics with a frontier AI foundation model called Kestrel. The capital infusion comes as the company’s first offering, Ataraxis Breast—the world’s first AI-native prognostic/predictive platform for breast cancer—was clinically validated in a landmark study to be 30 percent more accurate than the current standard of care for breast cancer. Ataraxis AI is on track to launch Ataraxis Breast for clinical use later this year for oncologists across
“This investment is a testament to the groundbreaking work our team is accomplishing and the immense potential of AI in precision medicine. It also reflects our progress, securing funding just a few months after receiving clinical validation,” said Jan Witowski, MD, PhD, co-founder and CEO, Ataraxis AI. “With this capital, we are on track to further accelerate our mission to change how cancer is treated and ultimately impact at least 50 percent of new cancer cases by 2030.”
Through novel optimization strategies and methodological sophistication, Kestrel beats existing state-of-the-art models with less required data and computational power. The model outperforms existing approaches by uncovering complex, previously undetectable patterns linked to patient outcomes across all disease types. Kestrel is the first of Ataraxis’ foundation models, which will power the development of treatment selection tools for all cancer types.
Ataraxis AI also announced its Clinical Advisory Board, which boasts an impressive roster of medical oncology key opinion leaders from top health systems, including: Dr. Francisco Esteva (Chief of Hematology and Medical Oncology at Northwell Lenox Hill), Dr. Lajos Pusztai (Co-Leader Genetics, Genomics and Epigenetics Program at Yale Cancer Center), Dr. Adam Brufsky (Co-Director of the Cancer Therapeutics Program at the UPMC Hillman Cancer Center), and Dr. Freya Schnabel (Director of Breast Surgery, NYU). These additions join Yann LeCun, PhD, Chief AI Scientist at Meta and Turing Award Laureate, who serves as the company’s AI advisor.
“In the next five years, the world’s leading oncology centers won’t just have top physicians—they’ll have AI copilots revolutionizing diagnosis and treatment. Ataraxis AI is at the forefront of this transformation, and its breakthrough platform, Kestrel, is setting a new standard for precision oncology,” said Krish Ramadurai, Partner at AIX Ventures. “Jan and his team aren’t just building another AI tool—they’re redefining how cancer is detected and treated, with the potential to improve millions of lives. We couldn’t be more excited to back them on this journey.”
About Ataraxis AI
Ataraxis is an AI precision medicine company transforming patient outcomes through the power of artificial intelligence. Backed by leading investors AIX Ventures, Floating Point, Bertelsmann Investments, Thiel Bio, Founders Fund, Giant Ventures, and Obvious Ventures, the company is addressing previously unsolvable problems in cancer prognosis and treatment selection through cutting-edge foundation models and multi-modal data. Ataraxis’ first clinically validated offering, Ataraxis Breast, is the world’s first AI-native prognostic/predictive platform for breast cancer and provides greater accuracy than standard of care genomic assays. To learn more, visit ataraxis.ai.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250304213795/en/
Media Contact
Pluck for Ataraxis AI
press@ataraxis.ai
Source: Ataraxis AI
FAQ
How much more accurate is Ataraxis Breast compared to current breast cancer care standards?
When will Ataraxis Breast be available for clinical use in the United States?
Who are the key investors in Ataraxis AI's $20.4M Series A funding round?
What is Ataraxis AI's goal for cancer treatment impact by 2030?
